This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tenney, D. J.
Right arrow Articles by Colonno, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tenney, D. J.
Right arrow Articles by Colonno, R. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2004, p. 3498-3507, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3498-3507.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

D. J. Tenney,1* S. M. Levine,1 R. E. Rose,1 A. W. Walsh,1 S. P. Weinheimer,1 L. Discotto,1 M. Plym,1 K. Pokornowski,1 C. F. Yu,1 P. Angus,2 A. Ayres,3 A. Bartholomeusz,3 W. Sievert,4 G. Thompson,3 N. Warner,3 S. Locarnini,3 and R. J. Colonno1

Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut,1 ARMC, Heidelberg,2 Department of Medicine, Monash University, Monash Medical Centre, Melbourne,4 Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia3

Received 19 March 2004/ Returned for modification 13 May 2004/ Accepted 24 May 2004

Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TCr) hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, two patients for whom previous therapies had failed exhibited virologic breakthrough while on ETV. Isolates from these patients (arbitrarily designated patients A and B) were analyzed genotypically for emergent substitutions in HBV reverse transcriptase (RT) and phenotypically for reduced susceptibility in cultures and in HBV polymerase assays. After 54 weeks of 3TC therapy, patient A (AI463901-A) received 0.5 mg of ETV for 52 weeks followed by a combination of ETV and 100 mg of 3TC for 89 weeks. Viral rebound occurred at 133 weeks after ETV was started. The 3TCr RT substitutions rtV173L, rtL180M, and rtM204V were present at study entry, and the additional substitutions rtI169T and rtM250V emerged during ETV-3TC combination treatment. Reduced ETV susceptibility in vitro required the rtM250V substitution in addition to the 3TCr substitutions. For liver transplant patient B (AI463015-B), previous famciclovir, ganciclovir, foscarnet, and 3TC therapies had failed, and RT changes rtS78S/T, rtV173L, rtL180M, rtT184S, and rtM204V were present at study entry. Viral rebound occurred after 76 weeks of therapy with ETV at 1.0 mg, with the emergence of rtT184G, rtI169T, and rtS202I substitutions within the preexisting 3TCr background. Reduced susceptibility in vitro was highest when both the rtT184G and the rtS202I changes were combined with the 3TCr substitutions. In summary, infrequent ETV resistance can emerge during prolonged therapy, with selection of additional RT substitutions within a 3TCr HBV background, leading to reduced ETV susceptibility and treatment failure.

* Corresponding author. Mailing address: Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Pkwy., Wallingford, CT 06492. Phone: (203) 677-7846. Fax: (203) 677-6088. E-mail: daniel.tenney{at}bms.com.

Antimicrobial Agents and Chemotherapy, September 2004, p. 3498-3507, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3498-3507.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jardi, R., Rodriguez-Frias, F., Tabernero, D., Homs, M., Schaper, M., Esteban, R., Buti, M. (2009). Use of the Novel INNO-LiPA Line Probe Assay for Detection of Hepatitis B Virus Variants That Confer Resistance to Entecavir Therapy. J. Clin. Microbiol. 47: 485-488 [Abstract] [Full Text]  
  • Tchesnokov, E. P., Obikhod, A., Schinazi, R. F., Gotte, M. (2008). Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase. J. Biol. Chem. 283: 34218-34228 [Abstract] [Full Text]  
  • Lau, D. T.-Y., Bleibel, W. (2008). Review: Current status of antiviral therapy for hepatitis B. Therapeutic Advances in Gastroenterology 1: 61-75 [Abstract]  
  • Chang, J.-M., Huang, K.-L., Yuan, T. T.-T., Lai, Y.-K., Hung, L.-M. (2008). The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice. Evid Based Complement Alternat Med 0: nem180v1-nem180 [Abstract] [Full Text]  
  • Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  
  • Schildgen, O., Shaw, T., Warner, N. (2007). Novel Lamivudine Resistance. Antimicrob. Agents Chemother. 51: 4533-4534 [Full Text]  
  • Price, N., Boxall, E. H. (2007). Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression. J Antimicrob Chemother 60: 1189-1192 [Abstract] [Full Text]  
  • Dougherty, A. M., Guo, H., Westby, G., Liu, Y., Simsek, E., Guo, J.-T., Mehta, A., Norton, P., Gu, B., Block, T., Cuconati, A. (2007). A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen Secretion. Antimicrob. Agents Chemother. 51: 4427-4437 [Abstract] [Full Text]  
  • Chang, J.-M., Cheng, C.-M., Hung, L.-M., Chung, Y.-S., Wu, R.-Y. (2007). Potential Use of Plectranthus amboinicus in the Treatment of Rheumatoid Arthritis. Evid Based Complement Alternat Med 0: nem168v1-nem168 [Abstract] [Full Text]  
  • Zhu, Y., Curtis, M., Snow-Lampart, A., Yang, H., Delaney, W., Miller, M. D., Borroto-Esoda, K. (2007). In Vitro Drug Susceptibility Analysis of Hepatitis B Virus Clinical Quasispecies Populations. J. Clin. Microbiol. 45: 3335-3341 [Abstract] [Full Text]  
  • Yao, G. (2007). Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 60: 201-205 [Abstract] [Full Text]  
  • Moriconi, F., Colombatto, P., Coco, B., Ciccorossi, P., Oliveri, F., Flichman, D., Maina, A. M., Sacco, R., Bonino, F., Brunetto, M. R. (2007). Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother 60: 341-349 [Abstract] [Full Text]  
  • Brunelle, M. N., Lucifora, J., Neyts, J., Villet, S., Holy, A., Trepo, C., Zoulim, F. (2007). In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants. Antimicrob. Agents Chemother. 51: 2240-2243 [Abstract] [Full Text]  
  • Delaney, W. E. IV (2007). Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother 59: 827-832 [Abstract] [Full Text]  
  • Langley, D. R., Walsh, A. W., Baldick, C. J., Eggers, B. J., Rose, R. E., Levine, S. M., Kapur, A. J., Colonno, R. J., Tenney, D. J. (2007). Inhibition of Hepatitis B Virus Polymerase by Entecavir. J. Virol. 81: 3992-4001 [Abstract] [Full Text]  
  • Tenney, D. J., Rose, R. E., Baldick, C. J., Levine, S. M., Pokornowski, K. A., Walsh, A. W., Fang, J., Yu, C.-F., Zhang, S., Mazzucco, C. E., Eggers, B., Hsu, M., Plym, M. J., Poundstone, P., Yang, J., Colonno, R. J. (2007). Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present. Antimicrob. Agents Chemother. 51: 902-911 [Abstract] [Full Text]  
  • Delaney, W. E. IV, Ray, A. S., Yang, H., Qi, X., Xiong, S., Zhu, Y., Miller, M. D. (2006). Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus.. Antimicrob. Agents Chemother. 50: 2471-2477 [Abstract] [Full Text]  
  • Osiowy, C., Villeneuve, J.-P., Heathcote, E. J., Giles, E., Borlang, J. (2006). Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2).. J. Clin. Microbiol. 44: 1994-1997 [Abstract] [Full Text]  
  • Myers, R., Clark, C., Khan, A., Kellam, P., Tedder, R. (2006). Genotyping Hepatitis B virus from whole- and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J. Gen. Virol. 87: 1459-1464 [Abstract] [Full Text]  
  • Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R., Apelian, D., the BEHoLD AI463022 Study Group, (2006). A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. NEJM 354: 1001-1010 [Abstract] [Full Text]  
  • Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., Colonno, R., Fernandes, L., the BEHoLD AI463027 Study Group, (2006). Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. NEJM 354: 1011-1020 [Abstract] [Full Text]  
  • Hoofnagle, J. H. (2006). Hepatitis B -- Preventable and Now Treatable. NEJM 354: 1074-1076 [Full Text]  
  • Jacquard, A.-C., Brunelle, M.-N., Pichoud, C., Durantel, D., Carrouee-Durantel, S., Trepo, C., Zoulim, F. (2006). In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2',3'-Dideoxy-3'-Fluoroguanosine. Antimicrob. Agents Chemother. 50: 955-961 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»